BIOCRYST PHARMACEUTICALS, INC. Proceeds from Issuance or Sale of Equity
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Proceeds from Issuance or Sale of Equity of $108.10 million as of 2020-06-01, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2023-02-27
- 2020-06-01: Proceeds from Issuance or Sale of Equity $108.10M; Proceeds from Issuance or Sale of Equity as first filed $107.67M.
- 2014-06-30: Proceeds from Issuance or Sale of Equity 1 month $106.60M.
- 2014-06-03: Proceeds from Issuance or Sale of Equity $107.80M.
- 2013-08-31: Proceeds from Issuance or Sale of Equity 1 month $18.50M.
| Period end | Proceeds from Issuance or Sale of Equity | Proceeds from Issuance or Sale of Equity as first filed | Proceeds from Issuance or Sale of Equity 1 month | Proceeds from Issuance or Sale of Equity 6 month |
|---|---|---|---|---|
| 2020-06-01 | $108.10M 10-K · filed 2023-02-27 | $107.67M 10-Q · filed 2020-08-07 | ||
| 2014-06-30 | $106.60M 10-K · filed 2015-03-02 | |||
| 2014-06-03 | $107.80M 10-K · filed 2016-02-26 | |||
| 2013-08-31 | $18.50M 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | $5.22M 10-Q · filed 2014-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |